echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Nat Commun: Polygenic Risk Score (PHS) to assess the risk of prostate cancer

    Nat Commun: Polygenic Risk Score (PHS) to assess the risk of prostate cancer

    • Last Update: 2021-03-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer is the second most common cancer among men in the world, and it causes a large number of morbidities and deaths.
    Screening for prostate cancercan reduce morbidity and mortality, and targeted and personalized diagnosis strategies can help avoid over-diagnosis and over-treatment of the disease.

    Prostate cancer is the second most common cancer among men in the world, and it causes a large number of morbidities and deaths.
    Prostate cancer is the second most common cancer among men in the world, and it causes a large number of morbidities and deaths.
    Screening diagnosis

    Previous studies have shown that genetic risk grading is expected to be used to determine individuals who are susceptible to cancer, and polygenic models can be used to assess the overall risk of disease development.
    The polygenic risk score is related to the age at diagnosis of prostate cancer patients, and can improve the accuracy of screening for Europeans.

    Genetic risk classification is expected to be used to determine individuals who are susceptible to cancer, and polygenic models can be used to assess the overall risk of disease development.
    Genetic risk classification is expected to be used to determine individuals who are susceptible to cancer, and polygenic models can be used to assess the overall risk of disease development.

    In this study, researchers evaluated the effect of polygenic risk score (PHS) on a multi-ethnic data set of 80,491 men (49,916 prostate patients and 30,575 controls).
    The results showed that the PHS score was related to the age of patients diagnosed with any aggressive cancer (Gleason score ≥7, T3-T4 stage, PSA ≥10ng/mL or lymph node metastasis/distant metastasis) and prostate cancer-specific death.

    The relationship between PHS and prostate cancer

    The results showed that in European (n=71,856), Asian (n=2,382) and African (n=6,253) populations, the association of cancer was very significant, and the risk ratios of prostate cancer were 5.
    54, 4.
    49 and 2.
    54, respectively.
    The risk ratios of prostate cancer, aggressive cancer and prostate cancer specific death were 5.
    32, 5.
    88, and 5.
    68, respectively.


    All in all, the study classified the risk of male prostate cancer patients in a multi-ethnic data set through a polygenic risk score to assess whether they have any aggressive and fatal prostate cancer.


    The data set also includes long-term follow-up information for patients to further assess the association between PHS and fatal prostate cancer.




    org/10.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.